The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC
暂无分享,去创建一个
N. Le Stang | A. Borczuk | I. Wistuba | L. Bubendorf | M. Mino‐Kenudson | D. Lin | F. Hirsch | Y. Yatabe | E. Brambilla | M. Beasley | S. Dacic | K. Kerr | M. Noguchi | G. Pelosi | M. Tsao | E. Thunnissen | N. Rekhtman | A. Moreira | S. Lantuejoul | M. Papotti | F. López-Ríos | T. Chou | W. Cooper | M. Wynes | A. Roden | L. Sholl | Gang Chen | A. Nicholson | Jin-Haeng Chung | J. Botling | D. Jain | John M. Longshore | N. Motoi | C. Poleri | M. Redman | A. Yoshida | J. Daigneault | D. Hwang | W. Travis
[1] Navneet Singh,et al. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer , 2020, Current Treatment Options in Oncology.
[2] M. Tsao,et al. Canadian Multicentre Project on Standardization of PD-L1 22C3 Immunohistochemistry Laboratory Developed Tests for Pembrolizumab Therapy in Non-Small Cell Lung Cancer. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[3] J. Mate,et al. The Immunohistochemical Expression of Programmed Death Ligand 1 (PD-L1) Is Affected by Sample Overfixation , 2020, Applied immunohistochemistry & molecular morphology : AIMM.
[4] Edward S. Kim,et al. The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] N. Girard,et al. PD-L1 Testing for Lung Cancer in 2019: Perspective from the IASLC Pathology Committee. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[6] C. Dooms,et al. Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays’ and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort , 2019, Modern Pathology.
[7] M. Copin,et al. P2.09-17 Real-World Concordance Across Pathologists for PD-L1 Scoring in Non-Small Cell Lung Cancer: Results from a Large Nationwide Initiative , 2019, Journal of Thoracic Oncology.
[8] S. Lam,et al. PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer. , 2019, Lung cancer.
[9] K. Syrigos,et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.
[10] C. Stubbs,et al. Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies , 2019, Modern Pathology.
[11] M. Péoc'h,et al. Impact of delayed fixation and decalcification on PD-L1 expression: a comparison of two clones , 2019, Virchows Archiv.
[12] E. Thunnissen,et al. Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen , 2019, Virchows Archiv.
[13] A. Calvo,et al. Programmed death–ligand 1 expression on direct Pap‐stained cytology smears from non–small cell lung cancer: Comparison with cell blocks and surgical resection specimens , 2019, Cancer cytopathology.
[14] Jianying Zhou,et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.
[15] A. Borczuk,et al. Immunocytochemistry for predictive biomarker testing in lung cancer cytology , 2019, Cancer cytopathology.
[16] Isaac E. Lloyd,et al. Characterization of PD-L1 Immunohistochemical Expression in Cell Blocks With Different Specimen Fixation and Processing Methods , 2017, Applied immunohistochemistry & molecular morphology : AIMM.
[17] A. Nicholson,et al. OA03.03 Phase 2B of Blueprint PD-L1 Immunohistochemistry Assay Comparability Study , 2018, Journal of Thoracic Oncology.
[18] A. Tafreshi,et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[19] Hui Yu,et al. PD‐L1 Immunohistochemistry Comparability Study in Real‐Life Clinical Samples: Results of Blueprint Phase 2 Project , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[20] P. Swanson,et al. Small Biopsies Misclassify up to 35% of PD-L1 Assessments in Advanced Lung Non–Small Cell Lung Carcinomas , 2018, Applied immunohistochemistry & molecular morphology : AIMM.
[21] V. Prieto,et al. Programmed death ligand 1 testing in non–small cell lung carcinoma cytology cell block and aspirate smear preparations , 2018, Cancer cytopathology.
[22] S. Novello,et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[23] L. Sholl,et al. Cytologic‐histologic correlation of programmed death‐ligand 1 immunohistochemistry in lung carcinomas , 2018, Cancer cytopathology.
[24] J. Juco,et al. Use of the 22C3 anti–programmed death‐ligand 1 antibody to determine programmed death‐ligand 1 expression in cytology samples obtained from non–small cell lung cancer patients , 2018, Cancer cytopathology.
[25] Jianrong Zhang,et al. Updated statistics of lung and bronchus cancer in United States (2018). , 2018, Journal of thoracic disease.
[26] D. Fujimoto,et al. Reduced Tumour Proportion Scores for Programmed Cell Death Ligand 1 in Stored Paraffin Tissue Sections. , 2018, Anticancer research.
[27] T. Morimoto,et al. Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[28] R. Trisolini,et al. Fading With Time of PD-L1 Immunoreactivity in Non–Small Cells Lung Cancer Tissues: A Methodological Study , 2016, Applied immunohistochemistry & molecular morphology : AIMM.
[29] A. Jemal,et al. Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.
[30] J. Heymann,et al. PD‐L1 expression in non‐small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens , 2017, Cancer cytopathology.
[31] Tarek Mekhail,et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[32] B. Skov,et al. Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx , 2017, Applied immunohistochemistry & molecular morphology : AIMM.
[33] J. Taube,et al. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer , 2017, JAMA oncology.
[34] S. Fox,et al. Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.
[35] D. Rimm,et al. Quantitative and Pathologist-Read comparison of the Heterogeneity of Programmed Death-Ligand 1(PD-L1) expression in Non-Small Cell Lung Cancer , 2016, Modern Pathology.
[36] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[37] Xiaoling Zhang,et al. Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer , 2015, Applied immunohistochemistry & molecular morphology : AIMM.
[38] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.